Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>Lantern Pharma uses AI & data to identify drug responders, uncover mechanism of action & rescue failed drugs.</li><li>It is developing LP-300 for non- & never smoker NSCLC in the Harmonic trial.</li><li>Secondary candidates include LP-100 for mCRPC and LP-184 and LP-284, which are in clinical development for multiple biomarker-defined tumors and hematological cancers, respectively.</li></ul>

Lantern Pharma uses AI & data to identify drug responders, uncover mechanism of action & rescue failed drugs.It is developing LP-300 for non- & never smoker NSCLC in the Harmonic trial.Secondary candidates include LP-100 for mCRPC and LP-184 and LP-284, which are in clinical development for multiple biomarker-defined tumors and hematological cancers, respectively.

LTRN: First Quarter 2025 Financial Results